Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. ViroGates AS's Pre-Tax Income for the
three
months ended in Mar. 2026 was €-0.40 Mil. ViroGates AS's Revenue for the
three
months ended in Mar. 2026 was €0.17 Mil. Therefore, ViroGates AS's pretax margin for the quarter that ended in Mar. 2026 was -228.74%.
The historical rank and industry rank for ViroGates AS's Pretax Margin % or its related term are showing as below:
FRA:EP2'
s Pretax Margin % Range Over the Past 10 Years
Min: -570.62 Med: -221.26 Max: -71.57
Current: -124.36
FRA:EP2's Pretax Margin % is ranked worse than 83.11% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs FRA:EP2: -124.36
ViroGates AS (FRA:EP2) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
ViroGates AS Pretax Margin % Related Terms
ViroGates AS Pretax Margin % Historical Data
* Premium members only.
The historical data trend for ViroGates AS's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:EP2 vs ABT, SYK, MDT: Pretax Margin % Comparison
For the Medical Devices subindustry, ViroGates AS's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where ViroGates AS's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ViroGates AS (FRA:EP2) has a Pretax Margin % of -228.74% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on ViroGates AS and its competitors. According to the industry distribution chart, ViroGates AS ranks #679 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 83.1%.
Is ViroGates AS's Pretax Margin % too high?
ViroGates AS's current Pretax Margin % is -228.74%. Based on the distribution chart, ViroGates AS ranks #679 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ViroGates AS has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Pretax Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #679 out of 817 companies for Pretax Margin %. This places ViroGates AS in the lower half of its industry. The industry median Pretax Margin % is 2.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.40, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on ViroGates AS and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current Pretax Margin % is -228.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
ViroGates AS (FRA:EP2) has a current Pretax Margin % of -228.74%. The stock's GF Value™ is €0.90, compared to a current price of €1.45 — trading 61.1% above its estimated fair value. The current Pretax Margin % is -228.74%. ViroGates AS's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For ViroGates AS (FRA:EP2), the current Pretax Margin % is -228.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (FRA:EP2) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of €1.45 is trading 61.1% above its estimated GF Value™ of €0.90.
Key valuation signals for FRA:EP2:
Pretax Margin %: -228.74%
GF Value™: €0.90 vs. price of €1.45 (61.1% above fair value)
No single metric tells the full story. See the FRA:EP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
44GF Score
Get the complete analysis for FRA:EP2
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EP2 has been successfully added to your 
